Bottom line
FHLC vs ETHSX: the short answer
FHLC (Fidelity MSCI Health Care Index ETF) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 63% by weight.
But FHLC is far broader, holding 337 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
FHLC is cheaper at 0.084% vs 1.18% — a difference of $110 a year per $10,000 invested.
Over five years, FHLC returned +7.2% a year vs +5.3% for ETHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
FHLC vs ETHSX side by side
| FHLC | ETHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Fidelity | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.084% | 1.18% |
| Annual cost per $10k | $8.4 | $118 |
| 10-yr cost on $10k (prospectus) | $108 | $1,911 |
| Max front load | None | 5.25% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +2.6% | −1.9% |
| 5-yr return (annualized) | +7.2% | +5.3% |
| 10-yr return (annualized) | +8.8% | +6.4% |
| Best quarter | +16.4% | +14.2% |
| Worst quarter | −13.1% | −12.1% |
| Net assets (fund) | $3.3B | $757.9M |
| Number of holdings | 337 | 42 |
| Portfolio turnover | 3% | 3% |
| Returns as of | Nov 30, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHLC | ETHSX | Difference |
|---|---|---|---|
| 2024 | +2.6% | +3.5% | −0.9% |
| 2023 | +2.5% | +5.7% | −3.2% |
| 2022 | −5.5% | −9.4% | +4.0% |
| 2021 | +20.4% | +22.1% | −1.7% |
| 2020 | +18.1% | +13.0% | +5.1% |
| 2019 | +21.9% | +26.0% | −4.1% |
| 2018 | +5.5% | +6.0% | −0.5% |
| 2017 | +23.3% | +16.2% | +7.1% |
| 2016 | −3.3% | −14.9% | +11.6% |
| 2015 | +7.0% | +8.4% | −1.3% |
Source: Fund prospectus bar charts
Holdings overlap
14 of FHLC's top 25 holdings also appear in ETHSX's top 25.
| Holding | FHLC | ETHSX |
|---|---|---|
| Eli Lilly & Co | 13.35% | 12.47% |
| Johnson & Johnson | 8.93% | 6.45% |
| AbbVie Inc | 6.42% | 6.46% |
| UnitedHealth Group Inc | 5.44% | 5.49% |
| Merck & Co Inc | 4.66% | 5.08% |
| Thermo Fisher Scientific Inc | 3.09% | 2.79% |
| Abbott Laboratories | 2.66% | 1.65% |
| Gilead Sciences Inc | 2.34% | 3.34% |
| Bristol-Myers Squibb Co | 1.93% | 4.25% |
| Intuitive Surgical Inc | 1.82% | 2.72% |
| Vertex Pharmaceuticals Inc | 1.76% | 3.38% |
| Stryker Corp | 1.62% | 2.21% |
| Medtronic PLC | 1.59% | 1.80% |
| Boston Scientific Corp | 1.00% | 2.18% |
Source: SEC Form N-PORT
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between FHLC and ETHSX?
Which is cheaper, FHLC or ETHSX?
Should I own both FHLC and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.